These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27788265)

  • 1. Correction: Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells.
    Attia SM; Ahmad SF; Ansari MA; Nadeem A; Al-Shabanah OA; Al-Harbi MM; Bakheet SA
    PLoS One; 2016; 11(10):e0165854. PubMed ID: 27788265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells.
    Attia SM; Ahmad SF; Ansaria MA; Nadeem A; Al-Shabanah OA; Al-Harbi MM; Bakheet SA
    PLoS One; 2016; 11(9):e0163703. PubMed ID: 27690233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexrazoxane mitigates epirubicin-induced genotoxicity in mice bone marrow cells.
    Attia SM; Ahmad SF; Saquib Q; Harisa GI; Al-Khedhairy AA; Bakheet SA
    Mutagenesis; 2016 Mar; 31(2):137-45. PubMed ID: 26399706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: Aneugenic effects of epirubicin in somatic and germinal cells of male mice.
    PLOS ONE Staff
    PLoS One; 2015; 10(2):e0118048. PubMed ID: 25695798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
    J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients.
    Galetta F; Franzoni F; Cervetti G; Cecconi N; Carpi A; Petrini M; Santoro G
    Biomed Pharmacother; 2005 Dec; 59(10):541-4. PubMed ID: 16325366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
    Basser RL; Sobol MM; Duggan G; Cebon J; Rosenthal MA; Mihaly G; Green MD
    J Clin Oncol; 1994 Aug; 12(8):1659-66. PubMed ID: 8040678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction: Utility of Corrected QT Interval in Orthostatic Intolerance.
    The
    PLoS One; 2015; 10(2):e0118166. PubMed ID: 25658596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.
    Aigner B; Bauernhofer T; Petru E; Niederkorn A; Arzberger EJ; Richtig E
    Dermatology; 2014; 229(4):288-92. PubMed ID: 25472626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Clinical Utility and Limitations of Intraoperative Monitoring of Visual Evoked Potentials.
    Luo Y; Regli L; Bozinov O; Sarnthein J
    PLoS One; 2015; 10(7):e0133819. PubMed ID: 26193358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane.
    Spallarossa P; Altieri P; Pronzato P; Aloi C; Ghigliotti G; Barsotti A; Brunelli C
    J Pharmacol Exp Ther; 2010 Jan; 332(1):87-96. PubMed ID: 19841470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction: CD34 Promotes Pathological Epi-Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy.
    Siemerink MJ; Hughes MR; Dallinga MG; Gora T; Cait J; Vogels IM; Yetkin-Arik B; Van Noorden CJ; Klaassen I; McNagny KM; Schlingemann RO
    PLoS One; 2016; 11(12):e0169061. PubMed ID: 28002489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction: Exploring the reproducibility of functional connectivity alterations in Parkinson's disease.
    Badea L; Onu M; Wu T; Roceanu A; Bajenaru O
    PLoS One; 2018; 13(5):e0197121. PubMed ID: 29723284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: Utility of Goldmann applanation tonometry for monitoring intraocular pressure in glaucoma patients with a history of laser refractory surgery.
    Lee SY; Bae HW; Kwon HJ; Seong GJ; Kim CY
    PLoS One; 2018; 13(10):e0206564. PubMed ID: 30359458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction: Limited Clinical Utility of Remote Ischemic Conditioning in Renal Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Zhou CC; Ge YZ; Yao WT; Wu R; Xin H; Lu TZ; Li MH; Song KW; Wang M; Zhu YP; Zhu M; Geng LG; Gao XF; Zhou LH; Zhang SL; Zhu JG; Jia RP
    PLoS One; 2018; 13(9):e0204184. PubMed ID: 30216391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction: Alterations in the gut bacterial microbiome in fungal Keratitis patients.
    Kalyana Chakravarthy S; Jayasudha R; Ranjith K; Dutta A; Pinna NK; Mande SS; Sharma S; Garg P; Murthy SI; Shivaji S
    PLoS One; 2019; 14(1):e0211757. PubMed ID: 30699192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction: Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement.
    PLOS ONE Staff
    PLoS One; 2017; 12(11):e0187909. PubMed ID: 29107944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction: Utility values for age-related macular degeneration patients in Korea.
    Choi S; Park SM; Jee D
    PLoS One; 2018; 13(12):e0209519. PubMed ID: 30550557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction: Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy.
    Hanganu A; Muthuraman M; Chirumamilla VC; Koirala N; Paktas B; Deuschl G; Zeuner KE; Groppa S
    PLoS One; 2017; 12(2):e0172374. PubMed ID: 28192485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.